摘要
α-葡萄糖苷酶抑制剂通过抑制小肠上段的α-葡萄糖苷酶延缓碳水化合物的吸收,从而改善餐后血糖。α-葡萄糖苷酶抑制剂在临床上常与其他降糖药物或心血管药物联合使用。本文通过系统地回顾国内外近年有关α-葡萄糖苷酶抑制剂与其他降糖药物或心血管药物联用的临床研究及病例报道,对药物联用安全性进行分析,以期为临床合理用药、保证临床用药安全提供科学依据。
Alpha-glucosidase inhibitor（AGI）is a kind of hypoglycemic agents that could delay the absorption of carbohydrates by inhibiting α-glucosidase in the upper part of the small intestine, thereby improving postprandial blood glucose. AGI is often used clinically with other hypoglycemic agents or cardiovascular drugs. We conducted a review on the adverse drug reactions （ADRs） of AGIs （acarbose, voglibose and miglitol） in combination with other hypoglycemic agents or cardiovascular drugs, in order to guide the rational use of AGIs in clinical practice, and provide scienti-c theoretical basis for the safety of these medications.
作者
苏青
SU Qing(Department of Endocrinology,Xinhua Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
出处
《药品评价》
CAS
2018年第23期3-8,45,共7页
Drug Evaluation
